226 related articles for article (PubMed ID: 26959297)
1. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.
Lilleby W; Stensvold A; Dahl AA
Acta Oncol; 2016 Jul; 55(7):807-13. PubMed ID: 26959297
[TBL] [Abstract][Full Text] [Related]
2. Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.
Lilleby W; Stensvold A; Dahl AA
Acta Oncol; 2014 Oct; 53(10):1380-9. PubMed ID: 24844918
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.
Lilleby W; Stensvold A; Dahl AA
Prostate; 2013 Jul; 73(10):1038-47. PubMed ID: 23532709
[TBL] [Abstract][Full Text] [Related]
4. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
5. Bother problems in prostate cancer patients after curative treatment.
Stensvold A; Dahl AA; Brennhovd B; Småstuen MC; Fosså SD; Lilleby W; Steinsvik A; Axcrona K; Smeland S
Urol Oncol; 2013 Oct; 31(7):1067-78. PubMed ID: 22341412
[TBL] [Abstract][Full Text] [Related]
6. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs.
Kyrdalen AE; Dahl AA; Hernes E; Hem E; Fosså SD
Prostate; 2010 Sep; 70(13):1480-9. PubMed ID: 20687221
[TBL] [Abstract][Full Text] [Related]
7. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
[TBL] [Abstract][Full Text] [Related]
8. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
Marchand V; Bourdin S; Charbonnel C; Rio E; Munos C; Campion L; Bonnaud-Antignac A; Lisbona A; Mahé MA; Supiot S
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1053-9. PubMed ID: 19880259
[TBL] [Abstract][Full Text] [Related]
9. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
12. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
13. Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Hayman J; Hole KH; Seierstad T; Perin J; DeWeese TL; Tran PT; Lilleby W
Urol Oncol; 2019 Apr; 37(4):289.e19-289.e26. PubMed ID: 30446451
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
16. Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.
Luo HC; Cheng LP; Cheng HH; Fu ZC; Liao SG; Li DS; Zheng WF; Lin GS; Zhu JF; Xu JF; Yin Q; Yu QY
Med Oncol; 2014 Jun; 31(6):991. PubMed ID: 24848281
[TBL] [Abstract][Full Text] [Related]
17. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
Fransson P; Lund JA; Damber JE; Klepp O; Wiklund F; Fosså S; Widmark A; ;
Lancet Oncol; 2009 Apr; 10(4):370-80. PubMed ID: 19286422
[TBL] [Abstract][Full Text] [Related]
19. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
20. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
